North Star Investment Management Corp. Sells 295 Shares of Eli Lilly and Company (NYSE:LLY)

North Star Investment Management Corp. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,188 shares of the company’s stock after selling 295 shares during the period. North Star Investment Management Corp.’s holdings in Eli Lilly and Company were worth $6,763,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Knightsbridge Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.9% in the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock worth $628,000 after buying an additional 15 shares during the last quarter. Centerpoint Advisory Group bought a new stake in Eli Lilly and Company in the fourth quarter worth about $514,000. LS Investment Advisors LLC boosted its stake in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after acquiring an additional 40 shares during the last quarter. CSM Advisors LLC grew its position in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after acquiring an additional 245 shares during the period. Finally, Proficio Capital Partners LLC increased its stake in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock worth $5,202,000 after purchasing an additional 1,562 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.8%

Shares of Eli Lilly and Company stock opened at $818.56 on Friday. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a 50-day moving average of $775.43 and a 200 day moving average of $801.59. The firm has a market cap of $775.78 billion, a price-to-earnings ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the previous year, the firm earned $2.58 EPS. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company’s payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on LLY shares. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.